Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Excellent find Titania - thank you for sharing
Speculation, but maybe the company has secured a grant of some sort to run their own trial. There's the Janssen connection as well of course. More speculation but topMD could be involved in some way as well.
He's named in the Activ 2 protocol docu - w an @ synairgen email address
Mark J. Main, PhD
Synairgen Research Ltd
Mailpoint 810, Level F
South Block
Southampton General Hospital
Tremona Road
Southampton
SO16 6YD
UK
https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.fnih.org/sites/default/files/final/pdf/Protocol-activ-2-A5401-version3-dated12.22.20.pdf&ved=2ahUKEwizkPej7qD7AhWbFMAKHRKPAIgQFnoECBcQAQ&usg=AOvVaw19EB9l0aLTbbNwvW9nZdcp
There's a profile pic on the LinkedIn page Doc83
So just to confirm - the mystery man from the pic is the chap that sold his respiratory treatment to Philip Morris? And he now has a respiratory and medical device consultancy?
Doc - I have seen Comms stating that NIH/strive are in talks w multiple pharma co's re trials but nothing re the maximum or total number of treatments to be trialed. Believe the flexibility to add more agents as and when they become available/appropriate is meant to be a major feature of Strive.
There are over 40 countries listed as participating and trial sites in the hundreds published so far.
Thinking about the current situation w Ensitrelvir and it almost certainly being on the market soon, being a 'better' version of pax -I have to think agreeing a protocol would be miles easier than SNG001 and the very particular requirements for a pivotal P3+ so it makes sense for them to be first. Plus it's already a success so easy win for NIH.
60 day endpoints is certainly interesting and leads to the obvious question of the same endpoints being applied to sprinter or Activ/home data and the results it would bring.
1500 patients is 500 short of the numbers SNG mentioned for a PT in a recent RNS
Tommy's point about the drug only showing efficacy in company led trials within 3 days of symptom onset seems pretty relevant. Curious if Shionogi actually lobbied to be on the trial or NIH insisted as they had brought the treatment through the Activ program and want to claim credit.
Overall, It's definitely good news the trial is happening given all the uncertainty and delays. Shionogi looks to offer a "better" option to pax although I guess we'll need real world data to know for sure. Expect the potential to test combination therapies is somewhere in the master protocol as well.
Understand there are other companies in advanced talks w NIH, so hopefully SNG is one of them, but if the company has other plans than so be it.
It's all really bullish, which is of course great to see and is probably a unique feature of being a uni spin out and being able to shout about your success and potential via a separate channel w/o breaking market rules.
Re the pipeline - I know SNG have a patent pending/submitted/published (I know nothing of this part of the industry tbh) for inhaled interferon lambada but, the statement would seem to also support potential other initiatives at UniS.
Just bumping this as there are two big things that stand out for me w this article
1. It is a positive write up of sprinter, I believe a first. Dare I say it paints sprinter as a success. Incredible how you get from 6 slides and a 15 min presentation to identify subgroup trends to two sentences in six months.
2. The author and publication are both genuinely professional, not the regurgitated, bit written market crap w are used to seeing.
SNG001 was associated with significant reduction in progression to severe disease or death
"Symptoms of long COVID-19 infection may be ameliorated in part with an experimental interferon (IFN)-ß-based inhaled treatment, according to study results presented at IDWeek 2022, held from October 19 to 23, in Washington, DC.
Between 1 and 5 individuals infected with SARS-CoV-2 experience a range of symptoms that can persist for months. As IFN-ß is key for defense against viral infection, a randomized controlled trial was conducted to evaluate the effects of an inhaled IFN-ß-1a nebulizer solution (SNG001) for decreasing hospitalization or recovery time. Although results of this trial showed no significant effects for its primary endpoints, SNG001 was associated with significant decreased risk for progression to severe disease or death.
In this analysis, researchers evaluated the effect of SNG001 on long COVID-19 symptoms. Patients with COVID-19 who required low-flow oxygen supplementation were randomly assigned to receive either SNG001 (n=314) or placebo (n=309) once daily for 14 days. Long COVID-19 symptoms were assessed at days 60 and 90 by telephone- or video call-based follow-up visits. Outcomes were evaluated using General Anxiety Disorder Questionnaire 7, Patient Health Questionnaire-9, Functional Assessment of Chronic Illness Therapy-Fatigue, and Brief Pain Inventory scale scores.
At follow-up, fewer SNG001 recipients reported loss of smell and/or taste (n=6 vs n=16; relative risk reduction [RRR], 61.4%; P =.003) and fatigue or malaise (n=27 vs n=43; RRR, 35.4%; P =.045) compared with placebo recipients, respectively. In addition, fewer SNG001 recipients reported dyspnea (n=23) than placebo recipients (n=33), however this difference did not reach statistical significance (RRR, 28.3%; P =.180).
This study may have been limited by not evaluating additional common symptoms of Long COVID-19.
According to the researchers, “these findings, suggesting SNG001 may be impacting common long COVID symptoms, provide additional support for the further investigation of SNG001.”
Some good pics from the ID week presentation included on the company twitter
https://twitter.com/Synairgenplc/status/1585890916396662786?t=eEKokAwYE6RgfPDn8RZCYg&s=19
My pleasure Joey
For those not bothered to click through, do note the disclaimer at the top of the session
"Abstracts are Embargoed until October 19 at 8 a.m. ET; Late Breaker Abstracts are Embargoed until the date and time of the presentation.*
https://www.eventscribe.net/2022/IDWeek/agenda.asp?startdate=10/21/2022&enddate=10/21/2022&BCFO=M&pfp=BrowseDay&mode=&fa=&fb=&fc=&fd=
Session: COVID-19 Late Breaking Abstracts
LB1533 - Impact of Treatment of Hospitalised COVID-19 Patients With Inhaled Interferon Beta-1a (SNG001) on Long COVID Symptoms: Results From the SPRINTER trial
Friday, October 21, 2022 2:35 PM – 2:45 PM US ET Location: 209 ABC
Live Stream
All relevant financial disclosures have been mitigated.